1
|
Castle PE, Faupel-Badger JM, Umar A, Rebbeck TR. A Proposed Framework and Lexicon for Cancer Prevention. Cancer Discov 2024; 14:594-599. [PMID: 38571411 DOI: 10.1158/2159-8290.cd-23-1492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2024]
Abstract
SUMMARY Cancer prevention is central to efforts to control the burden of cancer. We propose a new terminology framework to help guide these efforts and promote a key equity principle: "equal care for equal risk."
Collapse
Affiliation(s)
- Philip E Castle
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland
- Division of Cancer Epidemiology and Genetics, US National Cancer Institute, Rockville, Maryland
| | | | - Asad Umar
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland
| | - Timothy R Rebbeck
- Division of Population Science, Dana-Farber Cancer Institute; Zhu Family Center for Global Cancer Prevention and Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts
| |
Collapse
|
2
|
Faupel-Badger JM, Vogel AL, Hussain SF, Austin CP, Hall MD, Ness E, Sanderson P, Terse PS, Xu X, Balakrishnan K, Patnaik S, Marugan JJ, Rudloff U, Ferrer M. Teaching principles of translational science to a broad scientific audience using a case study approach: A pilot course from the National Center for Advancing Translational Sciences. J Clin Transl Sci 2022; 6:e66. [PMID: 35754433 PMCID: PMC9201875 DOI: 10.1017/cts.2022.374] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 03/02/2022] [Accepted: 03/04/2022] [Indexed: 11/06/2022] Open
Abstract
There are numerous examples of translational science innovations addressing challenges in the translational process, accelerating progress along the translational spectrum, and generating solutions relevant to a wide range of human health needs. Examining these successes through an education lens can identify core principles and effective practices that lead to successful translational outcomes. The National Center for Advancing Translational Sciences (NCATS) is identifying and teaching these core principles and practices to a broad audience via online courses in translational science which teach from case studies of NCATS-led or supported research initiatives. In this paper, we share our approach to the design of these courses and offer a detailed description of our initial course, which focused on a preclinical drug discovery and development project spanning academic and government settings. Course participants were from a variety of career stages and institutions. Participants rated the course high in overall value to them and in providing a unique window into the translational science process. We share our model for course development as well as initial findings from the course evaluation with the goal of continuing to stimulate development of novel education activities teaching foundational principles in translational science to a broad audience.
Collapse
Affiliation(s)
- Jessica M. Faupel-Badger
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Amanda L. Vogel
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Shadab F. Hussain
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | | | - Matthew D. Hall
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Elizabeth Ness
- National Institutes of Health, National Cancer Institute, Bethesda, MD, USA
| | - Philip Sanderson
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Pramod S. Terse
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Xin Xu
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Krishna Balakrishnan
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Samarjit Patnaik
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Juan J. Marugan
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| | - Udo Rudloff
- National Institutes of Health, National Cancer Institute, Bethesda, MD, USA
| | - Marc Ferrer
- National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, MD, USA
| |
Collapse
|
3
|
Wan KK, Davis D, Lee TN, Ford-Scheimer SL, Andreu AL, Bietrix F, Bryans J, Castro MT, Chiba N, Faupel-Badger JM, Haynes B, Hirasawa R, Morel CM, Souza TML, Morrow D, Munro T, Newman S, Ussi AE, Zorzal PB, Hall MD, Lo DC, Cutillo CM. A call to action for translational sciences in COVID-19 and future pandemics. Nat Rev Drug Discov 2022; 21:165-166. [PMID: 35091700 DOI: 10.1038/d41573-022-00020-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
4
|
Vogel AL, Knebel AR, Faupel-Badger JM, Portilla LM, Simeonov A. A systems approach to enable effective team science from the internal research program of the National Center for Advancing Translational Sciences. J Clin Transl Sci 2021; 5:e163. [PMID: 34527302 PMCID: PMC8427549 DOI: 10.1017/cts.2021.811] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 06/30/2021] [Accepted: 07/01/2021] [Indexed: 12/17/2022] Open
Abstract
The internal research program of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health aims to fundamentally transform the preclinical translational research process to get more treatments to more people more quickly. The program develops and implements innovative scientific and operational approaches that accelerate and enhance translation across many diverse projects. Cross-disciplinary team science is a defining feature of our organization, with scientists at all levels engaged in multiple research teams. Here, we share our systems approach to nurturing cross-disciplinary team science, which leverages organizational policies, structures, and processes. Policies including the organizational mission statement, principles for ethical conduct of research, performance review criteria, and training program objectives and approaches reinforce the value of team science to achieve the program's scientific goals. Structures including an organizational structure designed around solving translational problems, co-location of employees in a single state-of-the-art scientific facility, and shared-use laboratories, expertise and instrumentation facilitate collaboration. Processes including fluid team assembly, specialized project management, cross-agency partnerships, and decision making based on clear screening criteria and milestones enable effective team assembly and functioning. We share evidence of the impact of these approaches on the science and commercialization of findings and discuss pathways to broad adoption of similar approaches.
Collapse
Affiliation(s)
- Amanda L. Vogel
- National Institutes of Health (NIH); National Center for Advancing Translational Sciences (NCATS); Office of Policy, Communications and Education; Education Branch; Bethesda, MD, USA
| | - Ann R. Knebel
- National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI), Office of the Scientific Director, Rockville, MD, USA
| | - Jessica M. Faupel-Badger
- National Institutes of Health (NIH); National Center for Advancing Translational Sciences (NCATS); Office of Policy, Communications and Education; Education Branch; Bethesda, MD, USA
| | - Lili M. Portilla
- National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), Office of Strategic Alliances (OSA), Rockville, MD, USA
| | - Anton Simeonov
- National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI), Office of the Scientific Director, Rockville, MD, USA
| |
Collapse
|
5
|
Nelson DE, Faupel-Badger JM, Izmirlian G. Leadership Roles and Activities Among Alumni Receiving Postdoctoral Fellowship Training in Cancer Prevention. J Cancer Educ 2019; 34:526-534. [PMID: 29492801 DOI: 10.1007/s13187-018-1335-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
This study was conducted in 2016-2017 to better understand formal and informal leadership roles and activities of alumni from postdoctoral research training programs in cancer prevention. Data were obtained from surveys of 254 employed scientists who completed cancer prevention postdoctoral training within the National Cancer Institute (NCI) Cancer Prevention Fellowship Program, or at US research institutions through NCI-sponsored National Research Service Award (NRSA) individual postdoctoral fellowship (F32) grants, from 1987 to 2011. Fifteen questions categorized under Organizational Leadership, Research Leadership, Professional Society/Conference Leadership, and Broader Scientific/Health Community Leadership domains were analyzed. About 75% of respondents had at least one organizational leadership role or activity during their careers, and 13-34% reported some type of research, professional society/conference, or broader scientific/health community leadership within the past 5 years. Characteristics independently associated with leadership from regression models were being in earlier postdoctoral cohorts (8 items, range for statistically significant ORs = 2.8 to 10.8) and employment sector (8 items, range for statistically significant ORs = 0.4 to 11.7). Scientists whose race/ethnicity was other than white were less likely to report organizational leadership or management responsibilities (OR = 0.4, 95% CI 0.2-0.9). Here, many alumni from NCI-supported cancer prevention postdoctoral programs were involved in leadership, with postdoctoral cohort and employment sector being the factors most often associated with leadership roles and activities. Currently, there is relatively little research on leadership roles of biomedical scientists in general, or in cancer prevention specifically. This study begins to address this gap and provide a basis for more extensive studies of leadership roles and training of scientists.
Collapse
Affiliation(s)
- David E Nelson
- Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Jessica M Faupel-Badger
- Postdoctoral Research Associate Program, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Bethesda, MD, 20892-6200, USA.
| | - Grant Izmirlian
- Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
6
|
Faupel-Badger JM, Nelson DE, Izmirlian G. Career Satisfaction and Perceived Salary Competitiveness among Individuals Who Completed Postdoctoral Research Training in Cancer Prevention. PLoS One 2017; 12:e0169859. [PMID: 28121985 PMCID: PMC5266270 DOI: 10.1371/journal.pone.0169859] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2016] [Accepted: 12/22/2016] [Indexed: 11/26/2022] Open
Abstract
Studies examining career satisfaction of biomedical scientists are limited, especially in the context of prior postdoctoral training. Here we focused on career satisfaction defined as satisfaction with one’s career trajectory and perceived salary competitiveness among a predominantly Ph.D.-trained population of scientists who completed cancer prevention-related postdoctoral training between 1987–2011. National Cancer Institute (NCI) Cancer Prevention Fellowship Program (CPFP) alumni (n = 114), and previous recipients of NCI-sponsored Ruth L. Kirschstein National Research Service Award (NRSA/F32) postdoctoral fellowships (n = 140) completed online surveys. Associations of career satisfaction and perception of salary competitiveness with demographic, training, and employment-related factors were examined using logistic regression. Overall, 61% reported high levels of satisfaction with their career trajectory to-date. Higher salary (odds ratio [OR] = 2.86, 95% confidence interval [95% CI]: 1.07–7.69) and having more leadership roles (OR = 2.26, 95% CI:1.04–4.90) were independently associated with higher career satisfaction. Persons with race/ethnicity other than white (OR = 0.40, 95% CI: 0.20–0.82) or age ≥ 50 (OR = 0.40, 95%CI: 0.17–0.94) had lower career satisfaction levels. There were no statistically significant differences in career satisfaction levels by gender, scientific discipline, or employment sector. 74% perceived their current salary as competitive, but persons with 5–9, or ≥10 years in their current position reported lower levels (OR = 0.31, 95% CI: 0.15–0.65; and OR = 0.37, 95% CI: 0.16–0.87, respectively), as did individuals in government positions (OR = 0.33, 95% CI: 0.11–0.98). These data add to the understanding of career satisfaction of those with advanced training in biomedical research by examining these measures in relation to prior postdoctoral research training and across multiple career sectors.
Collapse
Affiliation(s)
- Jessica M. Faupel-Badger
- National Institute of General Medical Sciences, Bethesda, Maryland, United States of America
- * E-mail:
| | - David E. Nelson
- Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Grant Izmirlian
- Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America
| |
Collapse
|
7
|
Abstract
The hallmarks of premalignant lesions were first described in the 1970s, a time when relatively little was known about the molecular underpinnings of cancer. Yet it was clear there must be opportunities to intervene early in carcinogenesis. A vast array of molecular information has since been uncovered, with much of this stemming from studies of existing cancer or cancer models. Here, examples of how an understanding of cancer biology has informed cancer prevention studies are highlighted and emerging areas that may have implications for the field of cancer prevention research are described. A note of caution accompanies these examples, in that while there are similarities, there are also fundamental differences between the biology of premalignant lesions or premalignant conditions and invasive cancer. These differences must be kept in mind, and indeed leveraged, when exploring potential cancer prevention measures.
Collapse
Affiliation(s)
- Bríd M Ryan
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA..
| | | |
Collapse
|
8
|
Faupel-Badger JM, Nelson DE, Izmirlian G, Ross KH, Raue K, Tsakraklides S, Miyaoka A, Spiegelman M. Independent Association of Postdoctoral Training with Subsequent Careers in Cancer Prevention. PLoS One 2015; 10:e0144880. [PMID: 26659381 PMCID: PMC4682206 DOI: 10.1371/journal.pone.0144880] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Accepted: 11/24/2015] [Indexed: 11/25/2022] Open
Abstract
The purpose of this study was to examine the career paths of alumni from the National Cancer Institute (NCI) Cancer Prevention Fellowship Program (CPFP), a structured in-house postdoctoral training program of 3-4 years duration, and specifically what proportion of the alumni were currently performing cancer prevention-related activities. The analyses here included 119 CPFP alumni and 85 unsuccessful CPFP applicants, all of whom completed postdoctoral training between 1987-2011 and are currently employed. Postdoctoral training experiences and current career outcomes data were collected via online surveys. Differences between groups were assessed using chi-square and Fisher's exact test p-values and subsequent regression analyses adjusted for differences between the groups. Compared to 15.3% of unsuccessful CPFP applicants, 52.1% of CPFP alumni (odds ratio [OR] = 4.99, 95% confidence interval [95% CI): 1.91-13.0) were currently spending the majority of their time working in cancer prevention. Among those doing any cancer prevention-focused work, 54.3% of CPFP alumni spent the majority of their time performing cancer prevention research activities when compared to 25.5% of unsuccessful applicants (OR = 4.26, 95% CI: 1.38-13.2). In addition to the independent effect of the NCI CPFP, scientific discipline, and employment sector were also associated with currently working in cancer prevention and involvement in cancer prevention research-related activities. These results from a structured postdoctoral training program are relevant not only to the cancer prevention community but also to those interested in evaluating alignment of postdoctoral training programs with available and desired career paths more broadly.
Collapse
Affiliation(s)
| | - David E. Nelson
- Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Grant Izmirlian
- Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Katherine H. Ross
- Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Kimberley Raue
- Westat Incorporated, Rockville, Maryland, United States of America
| | | | - Atsushi Miyaoka
- Westat Incorporated, Rockville, Maryland, United States of America
| | - Maura Spiegelman
- Westat Incorporated, Rockville, Maryland, United States of America
| |
Collapse
|
9
|
Faupel-Badger JM, Raue K, Nelson DE, Tsakraklides S. Alumni perspectives on career preparation during a postdoctoral training program: a qualitative study. CBE Life Sci Educ 2015; 14:ar1. [PMID: 25673353 PMCID: PMC4353075 DOI: 10.1187/cbe.14-06-0102] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2014] [Revised: 09/18/2014] [Accepted: 09/21/2014] [Indexed: 05/25/2023]
Abstract
Published evaluations of career preparation of alumni from long-standing postdoctoral fellowship programs in the biomedical sciences are limited and often focus on quantitative analysis of data from extant publicly available sources. Qualitative methods provide the opportunity to gather robust information about specific program elements from structured postdoctoral training programs and the influence of this training on subsequent career paths of alumni. In-depth interviews with a subset of the National Cancer Institute's Cancer Prevention Fellowship Program (CPFP) alumni (n=27), representing more than 25 years of the program's history and multiple career sectors, were conducted to assess alumni reflections on the training environment and career preparation during their time in the CPFP. NVivo software was used to analyze data and identify major themes. Four main themes emerged from these interviews, including: the value of structured training curriculum, mentorship, transdisciplinary environment, and professional identity. Even when reflecting on training that occurred one to two decades earlier, alumni were able to highlight specific components of a structured postdoctoral training program as influencing their research and career trajectories. These results may have relevance for those interested in assessing how postdoctoral training can influence fellows throughout their careers and understanding salient features of structured programs.
Collapse
Affiliation(s)
- Jessica M. Faupel-Badger
- *Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-9712
| | | | - David E. Nelson
- *Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-9712
| | | |
Collapse
|
10
|
Waybright TJ, Xu X, Faupel-Badger JM, Xiao Z. Preparation of human serum for prolactin measurement by multiple reaction monitoring mass spectrometry. Methods Mol Biol 2014; 1002:195-203. [PMID: 23625405 DOI: 10.1007/978-1-62703-360-2_16] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The measurement of the protein hormone prolactin (PRL) in biological samples has developed over the years into a routine clinical assay aiding the diagnosis of multiple medical conditions. PRL is known to exist in multiple isoforms circulating throughout the body. Current methodologies for measuring the PRL levels typically involve a variety of immunoassays. However, most of these tests are not capable of distinguishing between the different isoforms. To address this need, we have developed a highly specialized method employing multiple reaction monitoring mass spectrometry (MRM-MS) capable of monitoring seven distinct peptides from two of the most common prolactin isoforms (the 23 kDa PRL and its 16 kDa N-terminal cleavage product). Since serum is the main source of clinical specimen for the measurement of prolactin isoforms, the method described in this chapter is focused on the approach to processing whole serum samples for prolactin analysis via reversed-phase liquid chromatography (RPLC) and MRM-MS.
Collapse
|
11
|
Chawla N, Kepka DL, Heckman-Stoddard BM, Horne HN, Felix AS, Luhn P, Pelser C, Barkley J, Faupel-Badger JM. Health disparities around the world: perspectives from the 2012 Principles and Practice of Cancer Prevention and Control course at the National Cancer Institute. J Oncol Pract 2013; 9:e284-9. [PMID: 24084887 PMCID: PMC3825291 DOI: 10.1200/jop.2013.001129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
INTRODUCTION The National Cancer Institute Principles and Practice of Cancer Prevention and Control course is a 4-week course encompassing a variety of cancer prevention and control topics that is open to attendees from medical, academic, government, and related institutions around the world. Themes related to the challenges health disparities present to cancer prevention efforts and potential solutions to these issues emerged from facilitated group discussions among the 2012 course participants. MATERIALS AND METHODS Small-group discussion sessions with participants (n = 85 from 33 different countries) and facilitators (n = 9) were held once per week throughout the 4-week course. Facilitators prepared open-ended questions related to course topics. Participants provided responses reflecting their opinions of topics on the basis of experiences in their countries. A thematic analysis was conducted to explore themes emerging from the discussion groups. RESULTS The varied influences of health disparities on cancer prevention efforts among > 30 countries represented prominent themes across discussion groups. Participants discussed the interplay of individual characteristics, including knowledge and culture, interpersonal relationships such as family structure and gender roles, community and organizational factors such as unequal access to health care and access to treatment, and national-level factors including policy and government structure. CONCLUSION The ideas and solutions presented here are from a geographically and professionally diverse group of individuals. The collective discussion highlighted the pervasiveness of health disparities across all areas represented by course participants and suggested that disparities are the largest impediment to achieving cancer prevention goals.
Collapse
Affiliation(s)
- Neetu Chawla
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Deanna L. Kepka
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Brandy M. Heckman-Stoddard
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Hisani N. Horne
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Ashley S. Felix
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Patricia Luhn
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Colleen Pelser
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Jonathan Barkley
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| | - Jessica M. Faupel-Badger
- National Cancer Institute, Bethesda, MD; University of Utah; and Huntsman Cancer Institute, Salt Lake City, UT
| |
Collapse
|
12
|
Faupel-Badger JM. Non-University Training Programs in Cancer Epidemiology, Emphasizing Participation from Low- and Middle-Income Countries. Cancer Epidemiol 2013. [DOI: 10.1093/med/9780199733507.003.0016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
13
|
Mason JL, Lei M, Faupel-Badger JM, Ginsburg EP, Seger YR, Dijoseph L, Schnell JD, Wiest JS. Outcome evaluation of the National Cancer Institute career development awards program. J Cancer Educ 2013; 28:9-17. [PMID: 23292841 PMCID: PMC3608862 DOI: 10.1007/s13187-012-0444-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
The National Cancer Institute (NCI) career development (K) awards program supports investigators to develop their cancer research programs and achieve independence. The NCI Center for Cancer Training conducted a K program evaluation by analyzing outcomes of awardees and individuals who applied to the program but were not funded. The evaluation covered seven NCI mechanisms (K01, K07, K08, K11, K22, K23, and K25) between 1980 and 2008. Descriptive statistics and regression modeling were performed on the full cohort (n = 2,893 individuals, 4,081 K applications) and a comparison cohort described herein. K awardees proportionately received more subsequent NIH grants and authored more publications, and time to first R01 grant was unaffected. Of those not pursuing research, K awardees were more likely to participate in activities signaling continued scientific engagement. The NCI K program had a positive impact, not only on participants' biomedical research careers but also on achieving outcomes significant to the scientific enterprise.
Collapse
|
14
|
Faupel-Badger JM, Arcaro KF, Balkam JJ, Eliassen AH, Hassiotou F, Lebrilla CB, Michels KB, Palmer JR, Schedin P, Stuebe AM, Watson CJ, Sherman ME. Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshop. J Natl Cancer Inst 2012; 105:166-74. [PMID: 23264680 DOI: 10.1093/jnci/djs505] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The pregnancy-lactation cycle (PLC) is a period in which the breast is transformed from a less-developed, nonfunctional organ into a mature, milk-producing gland that has evolved to meet the nutritional, developmental, and immune protection needs of the newborn. Cessation of lactation initiates a process whereby the breast reverts to a resting state until the next pregnancy. Changes during this period permanently alter the morphology and molecular characteristics of the breast (molecular histology) and produce important, yet poorly understood, effects on breast cancer risk. To provide a state-of-the-science summary of this topic, the National Cancer Institute invited a multidisciplinary group of experts to participate in a workshop in Rockville, Maryland, on March 2, 2012. Topics discussed included: 1) the epidemiology of the PLC in relation to breast cancer risk, 2) breast milk as a biospecimen for molecular epidemiological and translational research, and 3) use of animal models to gain mechanistic insights into the effects of the PLC on breast carcinogenesis. This report summarizes conclusions of the workshop, proposes avenues for future research on the PLC and its relationship with breast cancer risk, and identifies opportunities to translate this knowledge to improve breast cancer outcomes.
Collapse
Affiliation(s)
- Jessica M Faupel-Badger
- Cancer Prevention Fellowship Program and Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Forsythe LP, Gadalla SM, Hamilton JG, Heckman-Stoddard BM, Kent EE, Lai GY, Lin SW, Luhn P, Faupel-Badger JM. Enhancing a cancer prevention and control curriculum through interactive group discussions. J Cancer Educ 2012; 27:428-435. [PMID: 22661264 PMCID: PMC3540111 DOI: 10.1007/s13187-012-0376-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The Principles and Practice of Cancer Prevention and Control course (Principles course) is offered annually by the National Cancer Institute Cancer Prevention Fellowship Program. This 4-week postgraduate course covers the spectrum of cancer prevention and control research (e.g., epidemiology, laboratory, clinical, social, and behavioral sciences) and is open to attendees from medical, academic, government, and related institutions across the world. In this report, we describe a new addition to the Principles course syllabus, which was exclusively a lecture-based format for over 20 years. In 2011, cancer prevention fellows and staff designed and implemented small group discussion sessions as part of the curriculum. The goals of these sessions were to foster an interactive environment, discuss concepts presented during the Principles course, exchange ideas, and enhance networking among the course participants and provide a teaching and leadership opportunity to current cancer prevention fellows. Overall, both the participants and facilitators who returned the evaluation forms (n=61/87 and 8/10, respectively) reported a high satisfaction with the experience for providing both an opportunity to explore course concepts in a greater detail and to network with colleagues. Participants (93%) and facilitators (100%) stated that they would like to see this component remain a part of the Principles course curriculum, and both groups provided recommendations for the 2012 program. The design, implementation, and evaluation of this initial discussion group component of the Principles course are described herein. The findings in this report will not only inform future discussion group sessions in the Principles course but may also be useful to others planning to incorporate group learning into large primarily lecture-based courses.
Collapse
Affiliation(s)
- L P Forsythe
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, 20892, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Newhauser WD, Scheurer ME, Faupel-Badger JM, Clague J, Weitzel J, Woods KV. The future workforce in cancer prevention: advancing discovery, research, and technology. J Cancer Educ 2012; 27:S128-35. [PMID: 22314794 PMCID: PMC3349779 DOI: 10.1007/s13187-012-0328-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
As part of a 2-day conference on October 15 and 16, 2009, a nine-member task force composed of scientists, clinicians, educators, administrators, and students from across the USA was formed to discuss research, discovery, and technology obstacles to progress in cancer prevention and control, specifically those related to the cancer prevention workforce. This article summarizes the task force's findings on the current state of the cancer prevention workforce in this area and its needs for the future. The task force identified two types of barriers impeding the current cancer prevention workforce in research, discovery, and technology from reaching its fullest potential: (1) limited cross-disciplinary research opportunities with underutilization of some disciplines is hampering discovery and research in cancer prevention, and (2) new research avenues are not being investigated because technology development and implementation are lagging. Examples of impediments and desired outcomes are provided in each of these areas. Recommended solutions to these problems are based on the goals of enhancing the current cancer prevention workforce and accelerating the pace of discovery and clinical translation.
Collapse
Affiliation(s)
- Wayne D Newhauser
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Unit 1202, 1515 Holcombe Blvd., Houston, TX 77030, USA.
| | | | | | | | | | | |
Collapse
|
17
|
Faupel-Badger JM, Staff AC, Thadhani R, Powe CE, Potischman N, Hoover RN, Troisi R. Maternal angiogenic profile in pregnancies that remain normotensive. Eur J Obstet Gynecol Reprod Biol 2012; 158:189-93. [PMID: 21641103 DOI: 10.1016/j.ejogrb.2011.05.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Revised: 04/08/2011] [Accepted: 05/05/2011] [Indexed: 10/18/2022]
Abstract
OBJECTIVE We sought to determine if maternal characteristics are associated with angiogenic profile in the first and second trimester of normotensive pregnancies. STUDY DESIGN Circulating levels of maternal placental like growth factor (PlGF), soluble fms-like tyrosine kinase receptor (sFlt1), and soluble endoglin (sEng) were measured in serum samples collected during the first (median 11.3 weeks) and second trimester (median 17.1 weeks) of 182 normotensive pregnancies. Diastolic blood pressure (DBP), systolic blood pressure (SBP), and mean arterial pressure (MAP) were measured at the same visits when samples were collected to measure angiogenic factors. Linear regression analysis was used to examine associations of the angiogenic measures with maternal characteristics. The association between blood pressure measures and concentrations of angiogenic factors was evaluated using Spearman correlation and linear regression analysis. RESULTS In adjusted analyses, nulliparous women had higher sFlt1 concentrations in both first (p=0.06) and second (p=0.001) trimester. Higher BMI was associated with greater sFlt1 concentrations in both the first (p=0.004) and second trimester (p=0.008), but significantly lower sEng concentrations in both trimesters (p=0.002 for first trimester and p=0.0009 for second). Nulliparity and higher BMI also were associated with higher sFlt1/PLGF anti-angiogenic ratios in both first (p=0.05 and p=0.007, respectively) and second trimesters (p=0.003 and p=0.02, respectively). First trimester sFlt1 levels were weakly correlated with first trimester SBP (r(s)=0.18, p=0.03) and MAP (r(s)=0.16, p=0.04). Second trimester sEng levels were inversely associated with second trimester MAP (r(s)=-0.17, p=0.05). Including blood pressure measures in the linear regression models did not change the reported associations of angiogenic factors with maternal characteristics. CONCLUSIONS These results demonstrate that even early in normotensive pregnancies maternal characteristics are associated with variations in angiogenic profile across this population.
Collapse
Affiliation(s)
- Jessica M Faupel-Badger
- Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, Rockville, MD USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Faupel-Badger JM, Ginsburg E, Fleming JM, Susser L, Doucet T, Vonderhaar BK. 16 kDa prolactin reduces angiogenesis, but not growth of human breast cancer tumors in vivo. Discov Oncol 2011; 1:71-9. [PMID: 21113329 DOI: 10.1007/s12672-010-0012-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Prolactin (PRL) is a peptide hormone necessary for normal growth and development of the human breast. In addition, high levels of PRL in plasma correlate with increased risk of breast cancer, especially among postmenopausal women. Several isoforms of PRL exist in human circulation, including a 16 kDa isoform that is an N-terminal fragment of the full-length 23 kDa PRL. 16 kDa PRL has been shown to be anti-angiogenic in vitro and in vivo, and to reduce formation of tumors from prostate, colon and melanoma cancer cell lines. Here we explore the effect of 16 kDa PRL expression in vitro and in vivo using two breast cancer cell line models (MCF-7 and MDA-MB-231) and also the HCT-116 colon cancer cell line. In all three cell lines, 16 kDa PRL expression inhibited cell proliferation in vitro compared to empty vector controls. In vivo results were markedly different between the two types of cell lines. HCT-116 cells expressing 16 kDa PRL exhibited reduced vascularization and tumor formation, consistent with published results. The breast cancer cell lines expressing 16 kDa PRL also exhibited inhibition of angiogenesis in vivo but no reduction in tumor size or formation. These results suggest that the effects of 16 kDa PRL on tumor formation may vary across tissue types. The unique sensitivity of breast cancer to PRL as a mitogen and/or additional factors in the mammary gland environment (e.g. local hormone/mitogen concentration) may play a dominant role in tumor formation in vivo, thus outweighing the anti-angiogenesis effects and in vitro reduction in cell proliferation induced by 16 kDa PRL.
Collapse
Affiliation(s)
- J M Faupel-Badger
- Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | | | | | | | | | | |
Collapse
|
19
|
Faupel-Badger JM, van Bemmel DM, Wiest JS, Nelson DE. Expanding cancer prevention education to national and international audiences: the National Cancer Institute's Principles and Practice of Cancer Prevention and Control annual summer course. J Cancer Educ 2011; 26:619-625. [PMID: 21785976 PMCID: PMC3321923 DOI: 10.1007/s13187-011-0257-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The Summer Curriculum in Cancer Prevention has been sponsored by the National Cancer Institute's Cancer Prevention Fellowship Program for over two decades. This curriculum includes a 4-week course entitled "Principles and Practice of Cancer Prevention and Control." The ultimate goal of this course is to present the most current cancer prevention research to a diverse workforce of researchers and practitioners eager to address the current challenges in this field. The course covers the current status of cancer prevention research and practice, ranging from epidemiology and clinical practice, and from basic to behavioral science research. It is comprised of lectures grouped into nine modules representing broad and specific topics relevant to cancer prevention. Course participants come from a broad cross-section of career stages, professions, and research interests, and are from across the USA and other countries. Over time and in response to feedback from participants, the course has developed to meet the needs and expectations of this diverse audience, and may serve as a model for those interested in cancer prevention education and training in other countries.
Collapse
Affiliation(s)
- Jessica M Faupel-Badger
- National Cancer Institute, Cancer Prevention Fellowship Program, Bethesda, MD 20892-7105, USA.
| | | | | | | |
Collapse
|
20
|
Xu L, Wang SS, Healey MA, Faupel-Badger JM, Wilken JA, Battaglia T, Szabo E, Mao JT, Bergan RC. The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research. Cancer Prev Res (Phila) 2011; 4:616-21. [PMID: 21464034 DOI: 10.1158/1940-6207.capr-11-0018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
UNLABELLED The Ninth Annual AACR Frontiers in Cancer PREVENTION Research conference was held in Philadelphia in November 7-10, 2010. Its thematic focus was " PREVENTION From Basic Science to Public Health Benefit." Telomere plasticity, the microenvironment, inflammation, transformation to the metastatic phenotype, and pathways to obesity were highlighted as important elements of carcinogenesis amenable to intervention. The integration of information from novel technologies related to physical biology, molecular and genetic profiles, and imaging along with behavioral and clinical parameters have advanced risk stratification and early detection. Cancer prevention represents a powerful testing ground for the development of individually tailored intervention and for increasing the efficiency of drug discovery. Advances in clinical trials relate to more efficient design strategies, have shown first-in-human targeting capabilities, and have developed powerful strategies to overcome accrual barriers. Tailored intervention strategies now show high efficacy on large cohorts across several cancer types. These successes are expected to increase.
Collapse
Affiliation(s)
- Li Xu
- Department of Medicine, the Robert H LurieCancer Center of Northwestern University, Chicago, Illinois, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Faupel-Badger JM, Fichorova RN, Allred EN, Hecht JL, Dammann O, Leviton A, McElrath TF. Cluster analysis of placental inflammatory proteins can distinguish preeclampsia from preterm labor and premature membrane rupture in singleton deliveries less than 28 weeks of gestation. Am J Reprod Immunol 2011; 66:488-94. [PMID: 21623999 DOI: 10.1111/j.1600-0897.2011.01023.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
PROBLEM Inflammation within the preterm placenta is common and leads to adverse outcomes for premature infants. The risks of complications are different between iatrogenic (e.g. PE) and spontaneous (e.g. PL and membrane rupture) causes of preterm delivery, suggesting different underlying biology contributes to these placental conditions. METHOD OF STUDY Thirty preterm singleton placentas from the following groups were analyzed: (i) severe PE, (ii) preterm premature membrane rupture (pPROM), and (iii) PL. Proinflammatory and anti-inflammatory cytokines, adhesion and angiogenic molecules were measured in placental lysates using a multiplex assay. K-means cluster analysis was used to generate patterns of protein level intensity. RESULTS Three cluster patterns were apparent. Placentas from PE had high levels of vascular endothelial growth factor (VEGF) combined with low levels of acute inflammatory proteins (IL-1β, IL-18, IL-6, TNF-α), low IL-1 RA, and high transforming growth factor β (TGF-β). PL and pPROM had higher anti-inflammatory IL-1 RA and thrombomodulin combined with lower VEGF, regardless of proinflammatory cytokines and adhesion molecules. Half of the PL and pPROM cases had clusters of heightened inflammatory responses (lower TGF-β clustered with higher intensity of inflammatory mediators). CONCLUSION Discriminating protein patterns were elucidated and may serve as a foundation from which to understand the biologic mechanisms underlying these pregnancy complications.
Collapse
Affiliation(s)
- Jessica M Faupel-Badger
- Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892-7105, USA.
| | | | | | | | | | | | | |
Collapse
|
22
|
Nyante SJ, Faupel-Badger JM, Sherman ME, Pfeiffer RM, Gaudet MM, Falk RT, Andaya AA, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Chanock S, Garcia-Closas M, Figueroa JD. Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland. Breast Cancer Res 2011; 13:R42. [PMID: 21470416 PMCID: PMC3219205 DOI: 10.1186/bcr2864] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2010] [Revised: 03/09/2011] [Accepted: 04/06/2011] [Indexed: 12/27/2022] Open
Abstract
Introduction Studies suggest that high circulating levels of prolactin increase breast cancer risk. It is unclear if genetic variations in prolactin (PRL) or prolactin receptor (PRLR) genes also play a role. Thus, we examined the relationship between single nucleotide polymorphisms (SNPs) in PRL and PRLR, serum prolactin levels and breast cancer risk in a population-based case-control study. Methods We genotyped 8 PRL and 20 PRLR tag SNPs in 1965 breast cancer cases and 2229 matched controls, aged 20-74, and living in Warsaw or Łódź, Poland. Serum prolactin levels were measured by immunoassay in a subset of 773 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) for genotype associations with breast cancer risk were estimated using unconditional logistic regression, adjusted for age and study site. Geometric mean prolactin levels were estimated using linear regression models adjusted for age, study site, blood collection time, and menstrual cycle day (premenopausal women). Results Three SNPs were associated with breast cancer risk: in premenopausal women, PRLR rs249537 (T vs. C per-allele OR 1.39, 95% CI 1.07 - 1.80, P = 0.01); and in postmenopausal women, PRLR rs7718468 (C vs. T per-allele OR 1.16, 95% CI 1.03 - 1.30, P = 0.01) and PRLR rs13436213 (A vs. G per-allele OR 1.13 95% CI 1.01 - 1.26, P = 0.04). However, mean serum prolactin levels for these SNPs did not vary by genotype (P-trend > 0.05). Other SNPs were associated with serum prolactin levels: PRLR rs62355518 (P-trend = 0.01), PRLR rs10941235 (P-trend = 0.01), PRLR rs1610218 (P-trend = 0.01), PRLR rs34024951 (P-trend = 0.02), and PRLR rs9292575 (P-trend = 0.03) in premenopausal controls and PRL rs849872 (P-trend = 0.01) in postmenopausal controls. Conclusions Our data provide limited support for an association between common variations in PRLR and breast cancer risk. Altered serum prolactin levels were not associated with breast cancer risk-associated variants, suggesting that common genetic variation is not a strong predictor of prolactin-associated breast cancer risk in this population.
Collapse
Affiliation(s)
- Sarah J Nyante
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Yang HP, Black A, Falk RT, Brinton LA, Potischman N, Wentzensen N, Faupel-Badger JM, Sherman ME. Association of serum sex steroid hormone hemodilution and body mass index among healthy postmenopausal women. Ann Epidemiol 2011; 21:466-71. [PMID: 21435901 DOI: 10.1016/j.annepidem.2011.01.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2010] [Revised: 01/06/2011] [Accepted: 01/09/2011] [Indexed: 11/16/2022]
Abstract
PURPOSE Hemodilution refers to reduced concentrations of analytes in the blood secondary to increased fluid volume. Given that obesity is associated with expanded vascular volume, hemodilution may result in a lower ratio of blood concentrations of analytes among heavier subjects. Assessing the relationship of hormone concentration to total mass varies by body mass index (BMI) is etiologically important because obesity is related to hormone metabolism and cancer risk. METHODS We evaluated data for 194 postmenopausal controls in an endometrial cancer case-control study. Height, weight, and serum hormone concentrations were measured previously. We estimated serum hormone mass from concentration based on estimates of calculated plasma volume. We assessed the effect of BMI on relationships of sex steroid hormone concentration and mass using multivariate linear regression. RESULTS Higher BMI was associated with increased estrone, estrone sulfate, estradiol, and albumin-bound estradiol concentrations and masses (p-trend ≤ 0.001). With increasing BMI, androstenedione concentration did not change significantly (p-trend = 0.548), but its mass increased (p-trend = 0.024). CONCLUSIONS Relationships of sex steroid hormone concentration and mass were generally similar, except for androstenedione in which the relationship was only significant for mass. Future studies to assess both sex steroid hormone concentration and mass may have value in etiological research.
Collapse
Affiliation(s)
- Hannah P Yang
- Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Nyante SJ, Faupel-Badger JM, Sherman ME, Gaudet MM, Falk RT, Andaya AA, Pfeiffer RM, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Chanock SJ, Garcia-Closas M, Figueroa JD. Abstract P3-12-05: Genetic Variation in Prolactin and Prolactin Receptor, and Relationships with Serum Prolactin Levels and Breast Cancer Risk. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Studies support the hypothesis that high circulating levels of the hormone prolactin increase breast cancer risk. It remains unclear if genetic factors are associated with interindividual variation in circulating prolactin and subsequent breast cancer risk. We examined the relationship between single nucleotide polymorphisms (SNPs) in prolactin (PRL) and prolactin receptor (PRLR), serum prolactin levels and breast cancer risk in a population based case-control study.
Methods: We genotyped 8 PRL and 20 PRLR tag SNPs in 1943 cases and 2229 controls (82% and 89% of enrolled, respectively). Cases were women 20-74 years old, diagnosed with in situ or invasive breast cancer between 2000 and 2003, and living in Warsaw or Lodz, Poland. Controls were cancer-free women selected from a population registry, matched to cases on age and city. Blood samples were provided at the study interview. Serum prolactin levels were measured in a subset of 773 controls using the Bayer Advia Centaur immunoassay. Odds ratios and 95% CIs for genotype-breast cancer associations were estimated using unconditional logistic regression, adjusting for age and city. Geometric mean prolactin levels and 95% confidence intervals (CI) were estimated using linear regression, adjusting for age, city, blood collection time, and day of menstrual cycle (premenopausal). Log-additive model Wald P-values were used to test for linear trends. Analyses were stratified by menopausal status, and all statistical tests were 2-sided (alpha=0.05). To account for multiple comparisons, P-values were adjusted using the Benjamini and Hochberg method.
Results: Three PRLR SNPs were nominally associated with breast cancer: in premenopausal women, rs249537 (per-allele OR 1.39, 95% CI 1.07 - 1.82, P=0.0140); and in postmenopausal women, rs7718468 (per-allele OR 1.16, 95% CI 1.03 — 1.30, P=0.0137) and rs13436213 (per-allele OR 1.13 95% CI 1.01 — 1.26, P=0.0397). We examined serum prolactin levels by genotype for these three SNPs to determine whether the potential risk alleles were associated with increased circulating prolactin, but mean serum prolactin levels were similar by genotype in controls: rs249537 TT=3.83 ng/ml, CT=5.51 ng/ml, CC=5.50 ng/ml, P-trend=0.8381; rs7718468 CC=6.41 ng/ml, CT=6.86 ng/ml, TT=6.47 ng/ml, P-trend=0.5643; and rs13436213 AA=6.48 ng/ml, AG=6.52 ng/ml, GG=6.29 ng/ml, P-trend=0.4766. None of the nominal associations between PRLR genotypes and breast cancer risk were significant after adjusting for multiple comparisons (multiple comparison adjusted P-values: rs249537 P=0.4340; rs7718468 P=0.4340; rs13436213 P=0.8205). PRL SNPs were not associated with breast cancer risk in premenopausal or postmenopausal women. Discussion: Our data do not support an association between PRL or PRLR tag SNPs and breast cancer. Though some associations were nominally significant, these results may be due to random error and require further study. Furthermore, data do not support a relationship between riskassociated SNPs and differences in prolactin levels. Future research should focus on non-genetic factors that affect circulating prolactin levels.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-12-05.
Collapse
Affiliation(s)
- SJ Nyante
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - JM Faupel-Badger
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - ME Sherman
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - MM Gaudet
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - RT Falk
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - AA Andaya
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - RM Pfeiffer
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - J Lissowska
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - LA Brinton
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - B Peplonska
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - BK Vonderhaar
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - SJ Chanock
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - M Garcia-Closas
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| | - JD. Figueroa
- National Cancer Institute, Bethesda, MD; Albert Einstein College of Medicine, New York, NY; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lódz, Poland
| |
Collapse
|
25
|
Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer 2010; 103:1097-102. [PMID: 20736944 PMCID: PMC2965860 DOI: 10.1038/sj.bjc.6605844] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background: Previous prospective studies have found an association between prolactin (PRL) levels and increased risk of breast cancer. Using data from a population-based breast cancer case–control study conducted in two cities in Poland (2000–2003), we examined the association of PRL levels with breast cancer risk factors among controls and with tumour characteristics among the cases. Methods: We analysed PRL serum levels among 773 controls without breast cancer matched on age and residence to 776 invasive breast cancer cases with available pretreatment serum. Tumours were centrally reviewed and prepared as tissue microarrays for immunohistochemical analysis. Breast cancer risk factors, assessed by interview, were related to serum PRL levels among controls using analysis of variance. Mean serum PRL levels by tumour characteristics are reported. These associations also were evaluated using polytomous logistic regression. Results: Prolactin levels were associated with nulliparity in premenopausal (P=0.05) but not in postmenopausal women. Associations in postmenopausal women included an inverse association with increasing body mass index (P=0.0008) and direct association with use of recent/current hormone therapy (P=0.0006). In case-only analyses, higher PRL levels were more strongly associated with lobular compared with ductal carcinoma among postmenopausal women (P=0.02). Levels were not different by tumour size, grade, node involvement or oestrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 status. Conclusions: Our analysis demonstrates that PRL levels are higher among premenopausal nulliparous as compared with parous women. Among postmenopausal women, levels were higher among hormone users and lower among obese women. These results may have value in understanding the mechanisms underlying several breast cancer risk factor associations.
Collapse
Affiliation(s)
- J M Faupel-Badger
- Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, 6120 Executive Blvd (EPS), Suite 150E, MSC 7105, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Ziegler RG, Faupel-Badger JM, Sue LY, Fuhrman BJ, Falk RT, Boyd-Morin J, Henderson MK, Hoover RN, Veenstra TD, Keefer LK, Xu X. A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 2010; 121:538-45. [PMID: 20382222 PMCID: PMC6276800 DOI: 10.1016/j.jsbmb.2010.03.068] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2009] [Revised: 03/22/2010] [Accepted: 03/23/2010] [Indexed: 12/21/2022]
Abstract
Endogenous estrogen plays an integral role in the etiology of breast and endometrial cancer, and conceivably ovarian cancer. However, the underlying mechanisms and the importance of patterns of estrogen metabolism and specific estrogen metabolites have not been adequately explored. Long-standing hypotheses, derived from laboratory experiments, have not been tested in epidemiologic research because of the lack of robust, rapid, accurate measurement techniques appropriate for large-scale studies. We have developed a stable isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS(2)) method that can measure concurrently all 15 estrogens and estrogen metabolites (EM) in urine and serum with high sensitivity (level of detection=2.5-3.0fmol EM/mL serum), specificity, accuracy, and precision [laboratory coefficients of variation (CV's) < or =5% for nearly all EM]. The assay requires only extraction, a single chemical derivatization, and less than 0.5mL of serum or urine. By incorporating enzymatic hydrolysis, the assay measures total (glucuronidated+sulfated+unconjugated) EM. If the hydrolysis step is omitted, the assay measures unconjugated EM. Interindividual differences in urinary EM concentrations (pg/mL creatinine), which reflect total EM production, were consistently large, with a range of 10-100-fold for nearly all EM in premenopausal and postmenopausal women and men. Correlational analyses indicated that urinary estrone and estradiol, the most commonly measured EM, do not accurately represent levels of total urinary EM or of the other EM. In serum, all 15 EM were detected as conjugates, but only 5 were detected in unconjugated form. When we compared our assay methods with indirect radioimmunoassays for estrone, estradiol, and estriol and enzyme-linked immunosorbent assays for 2-hydroxyestrone and 16alpha-hydroxyestrone, ranking of individuals agreed well for premenopausal women [Spearman r (r(s))=0.8-0.9], but only moderately for postmenopausal women (r(s)=0.4-0.8). Our absolute readings were consistently lower, especially at the low concentrations characteristic of postmenopausal women, possibly because of improved specificity. We are currently applying our EM measurement techniques in several epidemiologic studies of premenopausal and postmenopausal breast cancer.
Collapse
Affiliation(s)
- R G Ziegler
- Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Faupel-Badger JM, Figueroa JD, Garcia-Closas M, Gaudet MM, Falk R, Andaya A, Pfeiffer R, Yang R, Lissowska J, Brinton L, Peplonska B, Vonderhaar BK, Sherman ME. Abstract 861: Relationships of prolactin serum levels to breast cancer risk and tumor characteristics in a population-based case-control study from Poland. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prolactin is a peptide hormone that is important in growth and development of the human breast. Prolactin also induces migration, proliferation, and survival of cancer cells in vitro and mammary gland tumorigenesis in animal models. Recent studies suggest that elevated serum prolactin levels are related to increased breast cancer risk, but confirmation and extension of these results are needed. Accordingly, we analyzed associations of serum prolactin levels with breast cancer risk using data from a population-based breast cancer case-control study conducted in Poland.
Methods: The Polish study included 2,386 consenting cases with pathologically confirmed breast cancer and 2,502 age and residency matched controls living in Warsaw and Lodz, Poland recruited during the years 2000 to 2003. Participation rates were 79% for cases and 69% for controls. This analysis included 773 cases and 776 controls with available serum and twofold representation of tumor in tissue microarrays. 70% of this study population was postmenopausal. Serum prolactin was measured by immunoassay at Quest Diagnostics. The overall CV for the prolactin serum assay was 99%. Detailed medical history and breast cancer risk factor information were obtained by interview. Tumor pathology data were collected via surgical pathology reports and independently reviewed in the U.S. Among controls, we assessed associations of prolactin levels with breast cancer risk factors using analysis of variance; case-control associations between breast cancer risk and prolactin levels (quartiles) were assessed by logistic regression.
Results: Among premenopausal controls, nulliparity was inversely associated with prolactin levels (p=0.05), whereas among postmenopausal women, current/recent use of combined hormone replacement therapy (p<0.0001) and lower body mass index (BMI, p<0.0001) were associated with higher prolactin levels. After adjustment for these and other known breast cancer risk factors, as well as for matching factors, elevated prolactin levels were significantly associated with postmenopausal breast cancer risk (OR=1.95; 95% CI 1.37-2.78, p<0.0001), when comparing the highest quartile of prolactin levels to the lowest. Among premenopausal women, risk also was elevated for all levels of prolactin, but risks were not significant and did not increase in a monotonic pattern.
Conclusions: Prolactin levels are significantly associated with breast cancer risk factors and risk for postmenopausal breast cancer. Our results confirm and extend prior studies focused on circulating prolactin levels and human breast cancer risk. Analyses examining associations between prolactin and tumor subclassifications based on immunological staining using tumor tissue microarrays are ongoing.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 861.
Collapse
Affiliation(s)
| | | | | | - Mia M. Gaudet
- 2Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | | | - Jolanta Lissowska
- 3M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | | | | | | | | |
Collapse
|
28
|
Faupel-Badger JM, Fuhrman BJ, Xu X, Falk RT, Keefer LK, Veenstra TD, Hoover RN, Ziegler RG. Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiol Biomarkers Prev 2010; 19:292-300. [PMID: 20056650 DOI: 10.1158/1055-9965.epi-09-0643] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Absolute and relative concentrations of estrogens and estrogen metabolites are important for clinical decisions as well as for epidemiologic, experimental, and clinical research on hormonal carcinogenesis. RIA and ELISA are routinely used for measuring estrogen metabolites in blood and urine due to efficiency and low cost. Here, we compare absolute and ranked concentrations of estrone, estradiol, and estriol measured by indirect RIA and of 2-hydroxyestrone and 16alpha-hydroxyestrone measured by ELISA to the concentrations obtained using a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which measures 15 estrogen metabolites concurrently. We used overnight urine samples collected from control women (362 premenopausal and 168 postmenopausal) participating in a population-based case-control study of breast cancer among Asian American women ages 20 to 55 years. When comparing RIA or ELISA levels to LC-MS/MS, absolute concentrations for the five estrogen metabolites ranged from 1.6 to 2.9 and 1.4 to 11.8 times higher in premenopausal and postmenopausal women, respectively (all P < 0.0001). However, LC-MS/MS measurements were highly correlated [Spearman r (r(s)) = 0.8-0.9] with RIA and ELISA measurements in premenopausal women and moderately correlated (r(s) = 0.4-0.8) in postmenopausal women. Measurements of the 2-hydroxyestrone:16alpha-hydroxyestrone ratio, a putative biomarker of breast cancer risk, were moderately correlated in premenopausal women (r(s) = 0.6-0.7) but only weakly correlated in postmenopausal women (r(s) = 0.2). LC-MS/MS had higher intraclass correlation coefficients (> or =99.6%) and lower coefficients of variation (< or =9.4%) than ELISA (> or =97.2% and < or =14.2%) and RIA (> or =95.2% and < or =17.8%). Comparison with the LC-MS/MS method suggests that the widely used RIA and ELISA estrogen metabolite measures may be problematic, especially at low estrogen metabolite levels characteristic of postmenopausal women.
Collapse
Affiliation(s)
- Jessica M Faupel-Badger
- Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, Bethesda, MD 20892-7105, USA.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Faupel-Badger JM, Hoover RN, Potischman N, Roberts JM, Troisi R. Pregnancy weight gain is not associated with maternal or mixed umbilical cord estrogen and androgen concentrations. Cancer Causes Control 2008; 20:263-7. [PMID: 18830676 DOI: 10.1007/s10552-008-9235-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2008] [Accepted: 09/09/2008] [Indexed: 10/21/2022]
Abstract
The association of maternal weight gain with serum hormone concentrations was explored in 75 women who had healthy, singleton pregnancies. Estradiol, estriol, estrone, androstenedione, testosterone, dehydroepiandrosterone (DHEA), and DHEA sulfate concentrations were measured both in maternal and mixed umbilical cord serum to assess hormone levels in both the maternal and fetal circulation at delivery. Our data show no association of maternal or cord steroid hormone concentrations with pregnancy weight gain. Increased exposure to steroid hormones, especially estrogens, during pregnancy has been hypothesized to play a role in subsequent breast cancer risk for both mother and female offspring. Our results are not consistent with an effect of pregnancy weight gain being mediated by this pathway as reflected by hormone concentrations at the end of pregnancy.
Collapse
Affiliation(s)
- Jessica M Faupel-Badger
- Division of Cancer Prevention and Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7105, USA.
| | | | | | | | | |
Collapse
|
30
|
Faupel-Badger JM, Hsieh CC, Troisi R, Lagiou P, Potischman N. Plasma volume expansion in pregnancy: implications for biomarkers in population studies. Cancer Epidemiol Biomarkers Prev 2007; 16:1720-3. [PMID: 17855687 DOI: 10.1158/1055-9965.epi-07-0311] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
There is a growing body of literature focused on endogenous hormone exposures during pregnancy and subsequent cancer risk for both mother and offspring. Examples of these studies include those focused on the biological mechanism for the association of preeclampsia with reduced risk of breast cancer for mother and female offspring or studies that have examined hormone concentrations during pregnancy between different ethnic groups who vary in their rates of breast cancer incidence. Although these studies seem relatively straightforward in conception and analysis, measurement of the concentration of hormones and other biomarkers in pregnant subjects is influenced by plasma volume expansion (PVE). During pregnancy, the maternal plasma volume expands 45% on average to provide for the greater circulatory needs of the maternal organs. Consequently, serum protein and hormone concentrations are greatly altered when comparing the pregnant with nonpregnant state. Assessing PVE also is complicated by the vast individual variation in PVE, ranging from minimal to a 2-fold increase. We propose that PVE needs to be evaluated when comparing biomarker concentrations during pregnancy in two populations that may differ with respect to PVE. Small body size is associated with lower PVE compared with higher body size. Therefore, we hypothesize that variation in PVE will influence the interpretation of differences in biomarker concentrations across population groups with respect to the etiologic significance of the biomarker to the disease under study (e.g., breast cancer). It is possible that some observations may be due only to differences in dilution between the two groups. We present PVE as a topic for consideration in population-based studies, examples of the types of studies where PVE may be relevant, and our own analysis of one such study in the text below.
Collapse
Affiliation(s)
- Jessica M Faupel-Badger
- Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, MSC 4254, 37 Convent Drive, Bethesda, MD 20892, USA.
| | | | | | | | | |
Collapse
|
31
|
Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J. Effects of Raloxifene on Circulating Prolactin and Estradiol Levels in Premenopausal Women at High Risk for Developing Breast Cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:1153-8. [PMID: 16775175 DOI: 10.1158/1055-9965.epi-05-0898] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Prolactin is a peptide hormone necessary for normal breast development that may contribute to breast tumorigenesis. Estrogen is a significant positive regulator of prolactin synthesis; therefore, raloxifene, a selective estrogen receptor modulator under study as a breast cancer prevention agent, may modulate both estradiol and prolactin levels by inhibiting estradiol from binding to its receptor. METHODS Premenopausal women at increased risk for invasive breast cancer participated in a pilot chemoprevention trial and were given 60 mg raloxifene daily for 24 months. Fasting serum samples collected at baseline and after 12 months on drug were used to measure circulating prolactin, estradiol, and sex hormone binding globulin (SHBG) levels. RESULTS Of the 27 subjects who completed 12 months of raloxifene, 23 had paired prolactin samples, and 20 had paired estradiol and SHBG samples. Prolactin levels did not significantly change with raloxifene treatment, but SHBG levels increased (mean change = 7.3 nmol/L; P = 0.0001; 95% confidence interval, 3.9-10.7). Estradiol (mean change = 42 pg/mL; P = 0.048; 95% confidence interval, 1-84 pg/mL) levels were elevated when comparing 15 of the 20 women with paired estradiol measurements who also had both of these samples taken during the early follicular phase of the menstrual cycle. CONCLUSIONS This report is the first to examine the long-term effects of raloxifene on prolactin, estradiol, and SHBG levels in premenopausal women who are also at increased risk for developing invasive breast cancer. Raloxifene had no significant effect on prolactin levels but did increase estradiol and SHBG measurements.
Collapse
MESH Headings
- Adult
- Biomarkers, Tumor/analysis
- Breast Neoplasms/blood
- Breast Neoplasms/drug therapy
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Intraductal, Noninfiltrating/blood
- Carcinoma, Intraductal, Noninfiltrating/drug therapy
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/drug therapy
- Estradiol/blood
- Female
- Humans
- Middle Aged
- Neoplasm Invasiveness/prevention & control
- Pilot Projects
- Premenopause
- Prolactin/blood
- Raloxifene Hydrochloride/therapeutic use
- Risk Factors
- Selective Estrogen Receptor Modulators/therapeutic use
- Sex Hormone-Binding Globulin/metabolism
Collapse
|
32
|
Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis. Oncogene 2003; 22:6679-89. [PMID: 14555981 DOI: 10.1038/sj.onc.1206830] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Mutations within members of the EGF/ErbB receptor family frequently release the oncogenic potential of these receptors, resulting in the activation of downstream signaling events independent of ligand regulatory constraints. We previously have demonstrated that the signal transduction events originating from S3-v-ErbB, a ligand-independent, oncogenic EGF receptor mutant, are qualitatively distinct from the ligand-dependent mitogenic signaling pathways associated with the wild-type EGF receptor. Specifically, expression of S3-v-ErbB in primary fibroblasts results in anchorage-independent growth, increased invasive potential, and the formation of a transformation-specific phosphoprotein signaling complex, all in a Ras-independent manner. Here we demonstrate the transformation-specific interaction between two components of this complex: the adaptor protein Grb2 and the cytoskeletal regulatory protein caldesmon. This interaction is mediated via both the amino-terminal SH3 and central SH2 domains of Grb2, and the amino-terminal (myosin-binding) domain of caldesmon. Expression of a dominant-negative Grb2 deletion mutant, which lacks the carboxy-terminal SH3 domain, in fibroblasts expressing S3-v-ErbB results in a reduction in phosphoprotein complex formation, the loss of anchorage-independent growth, and a reduction in invasive potential. Together, these results demonstrate a Ras-independent role for Grb2 in modulating cytoskeletal function during ligand-independent EGF receptor-mediated transformation, and provide further support for the hypothesis that ligand-independent oncogenic signaling is qualitatively distinct from ligand-dependent mitogenic signaling by the EGF receptor.
Collapse
Affiliation(s)
- Julie L Boerner
- Tumor Biology Program, Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First St SW, Rochester, MI 55905, USA
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 2002; 107:247-58. [PMID: 11775453 DOI: 10.1007/978-1-4757-3587-1_11] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/17/2023]
Abstract
In summary, the EGF/ErbB family of receptor tyrosine kinases has been shown to play a key role in normal ovarian follicle development, and cell growth regulation of the ovarian surface epithelium. Disregulation of these normal growth regulatory pathways, including overexpression and/or mutation of EGFR/ErbB receptor family members, as well as elements of their downstream signalling pathways, have been shown to contribute to the etiology and progression of epithelial ovarian cancer. It is, therefore, not surprising that these gene products, and their related soluble receptor isoforms may have clinical utility as tumor and/or serum biomarkers of disease activity. Moreover, since several of these soluble receptor isoforms have potent growth inhibitory activity, and are naturally occurring in the circulation, they are ideal candidates for the development of novel therapeutics for the treatment of ovarian cancer patients.
Collapse
Affiliation(s)
- N J Maihle
- Tumor Biology Program, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|